scholarly journals Role of recombinant human brain natriuretic peptide combined with sodium nitroprusside in improving quality of life and cardiac function in patients with acute heart failure

2020 ◽  
Author(s):  
Yang Peng ◽  
Han Wei
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Cardiac Function ◽  
Human Brain ◽  
Brain Natriuretic Peptide ◽  
Sodium Nitroprusside ◽  
Acute Heart Failure ◽  
Natriuretic Peptide

scholarly journals A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide

Medicine ◽  
2021 ◽  
Vol 100 (16) ◽  
pp. e25621
Author(s):  
Zhihua Pang ◽  
Chang Pan ◽  
Zhuhua Yao ◽  
Ying Ren ◽  
Liuyang Tian ◽  
...  
Keyword(s):  
Heart Failure ◽  
Human Brain ◽  
Brain Natriuretic Peptide ◽  
Acute Heart Failure ◽  
Natriuretic Peptide ◽  
Sequential Treatment

Limited value of brain natriuretic peptide as a prognostic marker in acute heart failure — A meta-analysis

2010 ◽  
Vol 145 (3) ◽  
pp. 540-541 ◽  
Author(s):  
Andrew Binder ◽  
Ignacio M. Seropian ◽  
Michael C. Kontos ◽  
Benjamin W. Van Tassell ◽  
Giuseppe G.L. Biondi-Zoccai ◽  
...  
Keyword(s):  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Acute Heart Failure ◽  
Natriuretic Peptide ◽  
Prognostic Marker ◽  
Meta Analysis

scholarly journals Waon Therapy Improves Quality of Life as Well as Cardiac Function and Exercise Capacity in Patients With Chronic Heart Failure

2015 ◽  
Vol 56 (2) ◽  
pp. 203-208 ◽  
Author(s):  
Mitsuo Sobajima ◽  
Takashi Nozawa ◽  
Yasutaka Fukui ◽  
Hiroyuki Ihori ◽  
Takashi Ohori ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cardiac Function ◽  
Exercise Capacity

HFrEF other treatment: revascularization

ESC CardioMed ◽  
2018 ◽  
pp. 1881-1884
Author(s):  
Eric Velazquez ◽  
Mark C. Petrie
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Coronary Artery Disease ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Common Cause ◽  
Reduced Ejection Fraction ◽  
Artery Disease

Although coronary artery disease is the most common cause of heart failure with reduced ejection fraction (HFrEF), the role of revascularization as a treatment strategy to improve survival, reduce morbidity, and enhance the quality of life has only begun to be investigated in recent years. To date, a sole randomized controlled clinical trial has been completed. This chapter summarizes what is currently known and what is unknown with respect to revascularization for the treatment of HFrEF.

Sign in / Sign up

Export Citation Format

Share Document